Atherosclerosis Supplements

1.2(top 50%)

impact factor

3.9K(top 5%)

papers

14.9K(top 20%)

citations

54(top 10%)

h-index

1.2(top 50%)

impact factor

13.6K

all documents

15.8K

doc citations

94(top 10%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)	Atherosclerosis Supplements	2004	1,636
2	ADMA and oxidative stress	Atherosclerosis Supplements	2003	360
3	Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase	Atherosclerosis Supplements	2002	274
4	The DDAH/ADMA/NOS pathway	Atherosclerosis Supplements	2003	259
5	NO and angiogenesis	Atherosclerosis Supplements	2003	229
6	Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease	Atherosclerosis Supplements	2005	198
7	Familial hypercholesterolaemia: A model of care for Australasia	Atherosclerosis Supplements	2011	181
8	Trans fatty acids – Effects on systemic inflammation and endothelial function	Atherosclerosis Supplements	2006	171
9	CVD risk factors and ethnicity—A homogeneous relationship?	Atherosclerosis Supplements	2006	169
10	Diabetic dyslipidemia	Atherosclerosis Supplements	2002	166
11	Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding	Atherosclerosis Supplements	2005	157
12	Statin inhibition of HMG-CoA reductase: a 3-dimensional view	Atherosclerosis Supplements	2003	154
13	The effect of the regulation on trans fatty acid content in Danish food	Atherosclerosis Supplements	2006	141
14	Paraoxonase and coronary heart disease	Atherosclerosis Supplements	2002	133
15	Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials	Atherosclerosis Supplements	2013	131
16	Markers of inflammation and their clinical significance	Atherosclerosis Supplements	2005	125
17	Comparative pharmacology of rosuvastatin	Atherosclerosis Supplements	2003	120
18	World-wide consumption of trans fatty acids	Atherosclerosis Supplements	2006	116
19	A trans world journey	Atherosclerosis Supplements	2006	110
20	Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency	Atherosclerosis Supplements	2010	110
21	Statins: Potential new indications in inflammatory conditions	Atherosclerosis Supplements	2006	107
22	PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA	Atherosclerosis Supplements	2004	106
23	Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography	Atherosclerosis Supplements	2013	102
24	Hugh Sinclair Lecture: The regulation and remodelling of HDL by plasma factors	Atherosclerosis Supplements	2002	100
25	ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease	Atherosclerosis Supplements	2003	95
26	Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA	Atherosclerosis Supplements	2003	95
27	Diagnostic algorithm for familial chylomicronemia syndrome	Atherosclerosis Supplements	2017	94
28	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration	Atherosclerosis Supplements	2016	90
29	Statins are diabetogenic – Myth or reality?	Atherosclerosis Supplements	2012	88
30	Trans fatty acids and cardiovascular disease—epidemiological data	Atherosclerosis Supplements	2006	87
31	HDL-C: Role as a risk modifier	Atherosclerosis Supplements	2011	87
32	The mechanism of the formation and secretion of chylomicrons	Atherosclerosis Supplements	2010	84
33	Novel aspects of postprandial lipemia in relation to atherosclerosis	Atherosclerosis Supplements	2008	83
34	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice	Atherosclerosis Supplements	2014	83
35	A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence	Atherosclerosis Supplements	2017	83
36	The origin of the statins	Atherosclerosis Supplements	2004	82
37	Trans fatty intakes during pregnancy, infancy and early childhood	Atherosclerosis Supplements	2006	82
38	Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase	Atherosclerosis Supplements	2003	79
39	Postprandial dyslipidemia in insulin resistance: Mechanisms and role of intestinal insulin sensitivity	Atherosclerosis Supplements	2008	77
40	The discovery and development of HMG-CoA reductase inhibitors	Atherosclerosis Supplements	2004	76
41	Pharmacological interactions of statins	Atherosclerosis Supplements	2002	72
42	Endothelial function in the post-prandial state	Atherosclerosis Supplements	2002	70
43	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy	Atherosclerosis Supplements	2015	66
44	Is insulin resistance atherogenic? Possible mechanisms	Atherosclerosis Supplements	2006	65
45	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study	Atherosclerosis Supplements	2017	65
46	Lipoprotein apheresis: State of the art and novelties	Atherosclerosis Supplements	2013	64
47	Do pregnancy complications and CVD share common antecedents?	Atherosclerosis Supplements	2004	63
48	Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatment goals	Atherosclerosis Supplements	2006	63
49	Reduction in intestinal cholesterol absorption by various food components: Mechanisms and implications	Atherosclerosis Supplements	2010	63
50	Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study	Atherosclerosis Supplements	2005	62

Scientometrics

Overviews

Citing Bodies

Atherosclerosis Supplements

Top Articles